Reflecting these findings, the 2022 consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) endorsed the use of SGLT2 inhibitors not only for heart failure management but also for reducing MACE and improving renal outcomes [38]. Here, SLC5A2 is linked to diabetes mellitus.